ALS News Today15h
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...
FierceBiotech2d
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
STAT2d
Can an epilepsy drug do more than reduce seizures?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Becker's Hospital Review2d
Google's ALS drug fails phase 3 trial
A clinical trial evaluating the drug fosigotifator in patients with amyotrophic lateral sclerosis has failed to meet its primary endpoint, according to topline results from the Healey ALS platform ...
Pharmaceutical Technology4d
Fosigotifator by Calico Life Sciences for Unspecified Central Nervous System Disorders: Likelihood of Approval
Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.
The Pharma Letter1d
Calico next to fail in ALS
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related ...
Crain's Chicago Business2d
AbbVie and rival's ALS drugs both disappoint in study
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...